Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

Archives of Internal Medicine

Volumn 170, Issue 14, 2010, Pages 1191-1201

  Nissen, Steven E ^a   Wolski, Kathy ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

AGE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SEX RATIO; SYSTEMATIC REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CONFIDENCE INTERVALS; DIABETES MELLITUS; EUROPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; THIAZOLIDINEDIONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77955285732     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.207     Document Type: Review

References (37)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published online May 21, 2007]. N Engl J Med. 2007;356(24):2457-2471. (Pubitemid 46919772)
2. Staff report on GlaxoSmithKline and the diabetes drug Avandia. The United States Senate Committee on Finance Web site. http://finance.senate.gov/ newsroom/ranking/release/?id=bc56b552-efc5-4706-968d-f7032d5cd2e4. Accessed May 7, 2010.
3. Benefit-risk assessment of rosiglitazone vs. pioglitazone. The United States Senate Committee on Finance Web site. http://finance.senate.gov/newsroom/ ranking/release/?id=bc56b552-efc5-4706-968d-f7032d5cd2e4. Accessed May 7, 2010.
4. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): amulticentre, randomised, open-label trial [published online June 6, 2009]. Lancet. 2009;373(9681):2125-2135.
5. Psaty BM, Prentice RL. Variation in event rates in trials of patients with type 2 diabetes. JAMA. 2009;302(15):1698-1700.
6. Nissen SE. Setting the RECORD straight. JAMA. 2010;303(12):1194-1195.
7. DeAngelis CD, Fontanarosa PB. Ensuring integrity in industry-sponsored research: primum non nocere, revisited. JAMA. 2010;303(12):1196-1198.
8. Nissen SE. The rise and fall of rosiglitazone. Eur Heart J. 2010;31(7):773-776.
9. Benbow A, Stewart M, Yeoman G. Thiazolidinediones for type 2 diabetes: all glitazones may exacerbate heart failure. BMJ. 2001;322(7280):236.
10. Cobitz A, Zambanini A, Sowell M. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiol Drug Saf. 2008;17(8):769-781 et al.
11. Glaxo agrees to post results of drug trials on Web site. The New York Times Web site. http://www.nytimes.com/2004/08/27/business/glaxo-agrees-to-post- results-of-drug-trials-on-web-site.html. Accessed May 7, 2010.
12. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-1195. (Pubitemid 47403105)
13. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death [published online August 6, 2007]. Ann Intern Med. 2007;147(8):578-581. (Pubitemid 351664507)
14. Briefing document: Division of Metabolism and Endocrine Products and Office of Surveillance and Epidemiology: joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. FDA Web site. http://www.fda.gov/ohrms/dockets/ac/07/ briefing/2007-4308b1-02-fda-backgrounder.pdf. Accessed May 7, 2010.
15. Rosen CJ. The rosiglitazone story - lessons from an FDA Advisory Committee meeting [published online August 8, 2007]. N Engl J Med. 2007;357(9):844-846. (Pubitemid 47347317)
16. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
17. Gerstein HC, Ratner RE, Cannon CP, et al; APPROACH Study Group. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History trial. Circulation. 2010;121(10):1176-1187.
18. Gerstein HC, Yusuf S, Bosch J, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096-1105.
19. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published online December 4, 2006]. N Engl J Med. 2006;355(23):2427-2443.
20. Clinical study register. GSK Web site. http://www.gsk- clinicalstudyregister.com/. Accessed May 7, 2010.
21. Drug approval package: Avandia (rosiglitazone maleate) tablets. FDAWeb site. http://www.accessdata.fda.gov/drugsatfda-docs/nda/99/21071-Avandia.cfm. Accessed May 7, 2010.
22. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI; Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes [published correction appears in J Clin Endocrinol Metab. 2001;86(4):1659 and 2002;2(1):iv]. J Clin Endocrinol Metab. 2001;86(1):280-288.
23. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A; Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes [published correction appears in Diabetes Care. 2001;24(5):973]. Diabetes Care. 2001;24(2):308-315.
24. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective inobese,insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab. 2003;5(3):163-170. (Pubitemid 36519349)
25. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial [published correction appears in JAMA. 2000;284:1384]. JAMA. 2000;283(13):1695-1702. (Pubitemid 30196209)
26. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26(1):53-77.
27. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? use and avoidance of continuity corrections in metaanalysis of sparse data [published correction appears in Stat Med. 2006;25:2700]. Stat Med. 2004;23(9):1351-1375.
28. Sutton A, Cooper N, Lambert P, Jones D, Abrams K, Sweeting M. Meta-analysis of rare and adverse event data. Expert Rev Pharmacoecon Outcomes Res. 2002;2:367-369.
29. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies. J Natl Cancer Inst. 1959;22(4):719-748.
30. Diabetes statistics. American Diabetes Association Web site. http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed May 7, 2010.
31. Diabetes facts. World Diabetes Federation Web site. http://www. worlddiabetesfoundation.org/composite-35.htm. Accessed May 7, 2010.
32. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis [published online June 5, 2007]. N Engl J Med. 2007;357(1):28-38.
33. Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289.
34. Goldberg RB, Kendall DM, Deeg MA, et al; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547-1554.
35. Hsiao A, Worrall DS, Olefsky JM, Subramaniam S. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics. 2004;20(17):3108-3127. (Pubitemid 39619201)
36. Wilson KD, Li Z, Wagner R, et al. Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality. PLoS One. 2008;3(7):e2609.
37. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. FDA Web site. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071627.pdf. Accessed May 7, 2010.